Connect public, paid and private patent data with Google Patents Public Datasets

Method of reducing interferences in an electrochemical sensor using two different applied potentials

Download PDF

Info

Publication number
US20100018878A1
US20100018878A1 US12574469 US57446909A US20100018878A1 US 20100018878 A1 US20100018878 A1 US 20100018878A1 US 12574469 US12574469 US 12574469 US 57446909 A US57446909 A US 57446909A US 20100018878 A1 US20100018878 A1 US 20100018878A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
electrode
current
working
glucose
interfering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12574469
Inventor
Oliver William Hardwicke Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeScan Scotland Ltd
Original Assignee
LifeScan Scotland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150015Source of blood
    • A61B5/150022Source of blood for capillary blood or interstitial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150206Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
    • A61B5/150274Manufacture or production processes or steps for blood sampling devices
    • A61B5/150282Manufacture or production processes or steps for blood sampling devices for piercing elements, e.g. blade, lancet, canula, needle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150358Strips for collecting blood, e.g. absorbent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150374Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
    • A61B5/150381Design of piercing elements
    • A61B5/150412Pointed piercing elements, e.g. needles, lancets for piercing the skin
    • A61B5/150435Specific design of proximal end
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150374Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
    • A61B5/150381Design of piercing elements
    • A61B5/150503Single-ended needles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • C12Q1/005Enzyme electrodes involving specific analytes or enzymes
    • C12Q1/006Enzyme electrodes involving specific analytes or enzymes for glucose
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28Electrolytic cell components
    • G01N27/30Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327Biochemical electrodes electrical and mechanical details of in vitro measurements
    • G01N27/3271Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
    • G01N27/3274Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration

Abstract

The present invention is directed to a method of reducing the effects of interfering compounds in the measurement of analytes and more particularly to a method of reducing the effects of interfering compounds in a system wherein the test strip utilizes two or more working electrodes. In one embodiment of the present invention, a first potential is applied to a first working electrode and a second potential, having the same polarity but a greater magnitude than the first potential, is applied to a second working electrode.

Description

    PRIORITY
  • [0001]
    This application claims priority from Provisional Application No. 60/516,252 filed Oct. 31, 2003, Provisional Application No. 60/558,728 filed Mar. 31, 2004, and Provisional Application No. 60/558,427 filed Mar. 31, 2004, which are incorporated herein by reference and to which we claim priority.
  • RELATED APPLICATIONS
  • [0002]
    The present invention is related to the following co-pending US Applications: U.S. patent application Ser. No. ______ [Attorney Docket Number DDI-5042], filed on Oct. 29, 2004; U.S. patent application Ser. No. ______ [Attorney Docket Number DDI-5064], filed on Oct. 29, 2004; U.S. patent application Ser. No. ______ [Attorney Docket Number DDI-5065], filed on Oct. 29, 2004; U.S. patent application Ser. No. ______ [Attorney Docket Number DDI-5066], filed on Oct. 29, 2004; and U.S. patent application Ser. No. ______ [Attorney Docket Number DDI-5067], filed on Oct. 29, 2004.
  • BACKGROUND OF INVENTION
  • [0003]
    Electrochemical glucose test strips, such as those used in the OneTouch® Ultra® whole blood testing kit, which is available from LifeScan, Inc., are designed to measure the concentration of glucose in a blood sample from patients with diabetes. The measurement of glucose is based upon the specific oxidation of glucose by the flavo-enzyme glucose oxidase. During this reaction, the enzyme becomes reduced. The enzyme is re-oxidised by reaction with the mediator ferricyanide, which is itself reduced during the course or the reaction. These reactions are summarized below.
  • [0000]

    D-Glucose+GOx (ox)→Gluconic acid+GOx (RED)
  • [0000]

    GOx (RED)+2Fe(CN)6 3−→GOx (OX)+2Fe(CN)6 4−
  • [0004]
    When the reaction set forth above is conducted with an applied potential between two electrodes, an electrical current may be created by the electrochemical re-oxidation of the reduced mediator ion (ferrocyanide) at the electrode surface. Thus, since, in an ideal environment, the amount of ferrocyanide created during the chemical reaction described above is directly proportional to the amount of glucose in the sample positioned between the electrodes, the current generated would be proportional to the glucose content of the sample. A redox mediator, such as ferricyanide is a compound that exchanges electrons between a redox enzyme such as glucose oxidase and an electrode. As the concentration of glucose in the sample increases, the amount of reduced mediator formed also increases, hence, there is a direct relationship between current resulting from the re-oxidation of reduced mediator and glucose concentration. In particular, the transfer of electrons across the electrical interface results in a flow of current (2 moles of electrons for every mole of glucose that is oxidized). The current resulting from the introduction of glucose may, therefore, be referred to as the glucose current.
  • [0005]
    Because it can be very important to know the concentration of glucose in blood, particularly in people with Diabetes, meters have been developed using the principals set forth above to enable the average person to sample and test their blood to determine the glucose concentration at any given time. The Glucose Current generated is monitored by the meter and converted into a reading of glucose concentration using a preset algorithm that relates current to glucose concentration via a simple mathematical formula. In general, the meters work in conjunction with a disposable strip that includes a sample chamber and at least two electrodes disposed within the sample chamber in addition to the enzyme (e.g. glucose oxidase) and mediator (e.g. ferricyanide). In use, the user pricks their finger or other convenient site to induce bleeding and introduces a blood sample to the sample chamber, thus starting the chemical reaction set forth above.
  • [0006]
    In electrochemical terms, the function of the meter is two fold. Firstly, it provides a polarizing voltage (approximately 0.4 V in the case of OneTouch® Ultra®) that polarizes the electrical interface and allows current flow at the carbon working electrode surface. Secondly, it measures the current that flows in the external circuit between the anode (working electrode) and the cathode (reference electrode). The meter may, therefore be considered to be a simple electrochemical system that operates in two-electrode mode although, in practice, third and, even fourth electrodes may be used to facilitate the measurement of glucose and/or perform other functions in the meter.
  • [0007]
    In most situations, the equation set forth above is considered to be a sufficient approximation of the chemical reaction taking place on the test strip and the meter reading a sufficiently accurate representation of the glucose content of the blood sample. However, under certain circumstances and for certain purposes, it may be advantageous to improve the accuracy of the measurement. For example, where a portion of the current measured at the electrode results from the presence of other chemicals or compounds in the sample. Where such additional chemicals or compounds are present, they may be referred to as interfering compounds and the resulting additional current may be referred to as Interfering Currents
  • [0008]
    Examples of potentially interfering chemicals (i.e. compounds found in physiological fluids such as blood that may generate Interfering Currents in the presence of an electrical field) include ascorbate, urate and acetaminophen (Tylenol™ or Paracetamol). One mechanism for generating Interfering Currents in an electrochemical meter for measuring the concentration of an analyte in a physiological fluid (e.g. a glucose meter) involves the oxidation of one or more interfering compounds by reduction of the enzyme (e.g. glucose oxidase). A further mechanism for generating Interfering Currents in such a meter involves the oxidation of one or more interfering compounds by reduction of the mediator (e.g. ferricyanide). A further mechanism for generating Interfering Currents in such a meter involves the oxidation of one or more interfering compounds at the working electrode. Thus, the total current measured at the working electrode is the superposition of the current generated by oxidation of the analyte and the current generated by oxidation of interfering compounds. Oxidation of interfering compounds may be a result of interaction with the enzyme, the mediator or may occur directly at the working electrode.
  • [0009]
    In general, potentially interfering compounds can be oxidized at the electrode surface and/or by a redox mediator. This oxidation of the interfering compound in a glucose measurement system causes the measured oxidation current to be dependent on both the glucose and the interfering compound. Therefore, if the concentration of interfering compound oxidizes as efficiently as glucose and/or the interfering compound concentration is significantly high relative to the glucose concentration, it may impact the measured glucose concentration.
  • [0010]
    The co-oxidization of analyte (e.g. glucose) with interfering compounds is especially problematic when the standard potential (i.e. the potential at which a compound is oxidized) of the interfering compound is similar in magnitude to the standard potential of the redox mediator, resulting in a significant portion of the Interference Current being generated by oxidation of the interfering compounds at the working electrode. Electrical current resulting from the oxidation of interfering compounds at the working electrode may be referred to as direct interference current. It would, therefore, be advantageous to reduce or minimize the effect of the direct interference current on the measurement of analyte concentration. Previous methods of reducing or eliminating direct interference current include designing test strips that prevent the interfering compounds from reaching the working electrode, thus reducing or eliminating the direct interference current attributable to the excluded compounds.
  • [0011]
    One strategy for reducing the effects of interfering compounds that generate Direct interference current is to place a negatively charged membrane on top of the working electrode. As one example, a sulfonated fluoropolymer such as NAFION™ may be placed over the working electrode to repel all negatively charged chemicals. In general, many interfering compounds, including ascorbate and urate, have a negative charge, and thus, are excluded from being oxidized at the working electrode when the surface of the working electrode is covered by a negatively charged membrane. However, because some interfering compounds, such as acetaminophen, are not negatively charged, and thus, can pass through the negatively charged membrane, the use of a negatively charged membrane will not eliminate the Direct interference current. Another disadvantage of covering the working electrode with a negatively charged membrane is that commonly used redox mediators, such as ferricyanide, are negatively charged and cannot pass through the membrane to exchange electrons with the electrode. A further disadvantage of using a negatively charged membrane over the working electrode is the potential to slow the diffusion of the reduced mediator to the working electrode, thus increasing the test time. A further disadvantage of using a negatively charged membrane over the working electrode is the increased complexity and expense of manufacturing the test strips with a negatively charged membrane.
  • [0012]
    Another strategy that can be used to decrease the effects of Direct Interfering Currents is to position a size selective membrane on top of the working electrode. As one example, a 100 Dalton size exclusion membrane such as cellulose acetate may be placed over the working electrode to exclude compounds having a molecular weight greater than 100 Daltons. In this embodiment, the redox enzyme such as glucose oxidase is positioned over the size exclusion membrane. Glucose oxidase generates hydrogen peroxide, in the presence of glucose and oxygen, in an amount proportional to the glucose concentration. It should be noted that glucose and most redox mediators have a molecular weight greater than 100 Daltons, and thus, cannot pass through the size selective membrane. Hydrogen peroxide, however, has a molecular weight of 34 Daltons, and thus, can pass through the size selective membrane. In general, most interfering compounds have a molecular weight greater than 100 Daltons, and thus, are excluded from being oxidized at the electrode surface. Since some interfering compounds have smaller molecular weights, and thus, can pass through the size selective membrane, the use of a size selective membrane will not eliminate the Direct interference current. A further disadvantage of using a size selective membrane over the working electrode is the increased complexity and expense of manufacturing the test strips with a size selective membrane.
  • [0013]
    Another strategy that can be used to decrease the effects of Direct interference current is to use a redox mediator with a low redox potential, for example, a redox potential of between about −300 mV to +100 mV (vs a saturated calomel electrode). This allows the applied potential to the working electrode to be relatively low which, in turn, decreases the rate at which interfering compounds are oxidized by the working electrode. Examples of redox mediators having a relatively low redox potential include osmium bipyridyl complexes, ferrocene derivatives, and quinone derivatives. However, redox mediators having a relatively low potential are often difficult to synthesize, relatively unstable and relatively insoluble.
  • [0014]
    Another strategy that can be used to decrease the effects of interfering compounds is to use a dummy electrode in conjunction with the working electrode. The current measured at the dummy electrode may then be subtracted from the current measured at the working electrode in order to compensate for the effect of the interfering compounds. If the dummy electrode is bare (i.e. not covered by an enzyme or mediator), then the current measured at the dummy electrode will be proportional to the Direct interference current and subtracting the current measured at the dummy electrode from the current measured at the working electrode will reduce or eliminate the effect of the direct oxidation of interfering compounds at the working electrode. If the dummy electrode is coated with a redox mediator then the current measured at the dummy electrode will be a combination of Direct interference current and interference current resulting from reduction of the redox mediator by an interfering compound. Thus, subtracting the current measured at the dummy electrode coated with a redox mediator from the current measured at the working electrode will reduce or eliminate the effect of the direct oxidation of interfering compounds and the effect of interference resulting from reduction of the redox mediator by an interfering compound at the working electrode. In some instances the dummy electrode may also be coated with an inert protein or deactivated redox enzyme in order to simulate the effect of the redox mediator and enzyme on diffusion. Because it is preferable that test strips have a small sample chamber so that people with diabetes do not have to express a large blood sample, it may not be advantageous to include an extra electrode which incrementally increases the sample chamber volume where the extra electrode is not used to measure the analyte (e.g. glucose). Further, it may be difficult to directly correlate the current measured at the dummy electrode to interference currents at the working electrode. Finally, since the dummy electrode may be coated with a material or materials (e.g. redox mediator) which differ from the materials used to cover the working electrode (e.g. redox mediator and enzyme), test strips which use dummy electrodes as a method of reducing or eliminating the effect of interfering compounds in a multiple working electrode system may increase the cost and complexity of manufacturing the test strip.
  • [0015]
    Certain test strip designs which utilize multiple working electrodes to measure analyte, such as the system used in the OneTouch® Ultra® glucose measurement system are advantageous because the use of two working electrodes. In such systems, it would, therefore, be advantageous to develop a method of reducing or eliminating the effect of interfering compounds. More particularly, it would be advantageous to develop a method of reducing or eliminating the effect of interfering compounds without utilizing a dummy electrode, an intermediate membrane or a redox mediator with a low redox potential.
  • SUMMARY OF INVENTION
  • [0016]
    The present invention is directed to a method of reducing the effects of interfering compounds in the measurement of analytes and more particularly to a method of reducing the effects of interfering compounds in a system wherein the test strip utilizes two or more working electrodes. In one embodiment of the present invention, a first potential is applied to a first working electrode and a second potential, having the same polarity but a greater magnitude than the first potential, is applied to a second working electrode. The magnitude of the second potential may also be less than the first potential for an embodiment where a reduction current is used to measure the analyte concentration. In one embodiment, the first working electrode and second working electrode may be covered with an enzyme reagent and redox mediator that are analyte specific. The first potential applied to the first working electrode is selected such that it is sufficient to oxidize reduced redox mediator in a diffusion limited manner while the second potential is selected to have a magnitude (i.e. absolute value) greater than the magnitude of the first potential, resulting in a more efficient oxidation of at the second working electrode. In this embodiment of the invention, the current measured at the first working electrode includes an analyte current and interfering compound current while the current measured at the second working electrode includes an analyte overpotential current and an interfering compound overpotential current. It should be noted that the analyte current and the analyte overpotential current both refer to a current that corresponds to the analyte concentration and that the current is a result of a reduced mediator oxidation. In an embodiment of this invention, the relationship between the currents at the first working electrode and second working electrode may be defined by the following equation,
  • [0000]
    A 1 = W 2 - YW 1 X - Y
  • [0000]
    where A1 is the analyte current at the first working electrode, W1 is the current measured at the first working electrode, W2 is the current measured at the second working electrode, X is an analyte dependent voltage effect factor and Y is an interfering compound dependent voltage effect factor. Using the equation set forth above, in a method according to the present invention, it is possible to reduce the effect of oxidation currents resulting from the presence of interfering compounds and calculate a corrected current value that is more representative of the concentration of analyte in the sample being measured.
  • [0017]
    In one embodiment of the present invention, the concentration of glucose in a sample placed on a test strip can be calculated by placing the sample on a test strip having a first working electrode and second working electrode and a reference electrode, at least the first working electrode and second working electrodes being coated with chemical compounds (e.g. an enzyme and a redox mediator) adapted to facilitate the oxidation of glucose and the transfer of electrons from the oxidized glucose to the first working electrode and the second working electrode when a potential is applied between the first working electrode and the reference electrode, and the second working electrode and the reference electrode. In accordance with the present invention, a first potential is applied between the first working electrode and the reference electrode, the first potential being selected to have a magnitude sufficient to ensure that the magnitude of the current generated by oxidation of the glucose in the sample is limited only by factors other than applied voltage (e.g. diffusion). In accordance with the present invention, a second potential is applied between the second working electrode and the reference electrode, the second potential being greater in magnitude than the first potential and, in one embodiment of the present invention, the second potential being selected to increase the oxidation of interfering compounds at the second working electrode. In a further embodiment of the present invention, the following equation may be used to reduce the effect of oxidation current resulting from the presence of interfering compounds on the current used to calculate the concentration of glucose in the sample. In particular, the glucose concentration may be derived using a calculated current A1G where:
  • [0000]
    A 1 G = W 2 - YW 1 X G - Y
  • [0000]
    where A1G is a glucose current, W1 is the current measured at the first working electrode, W2 is the current measured at the second working electrode, XG is a glucose dependent voltage effect factor and Y is an interfering compound dependent voltage effect factor.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0018]
    The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
  • [0019]
    FIG. 1 is an exploded perspective view of a test strip embodiment for use in the present invention.
  • [0020]
    FIG. 2 is a schematic view of a meter and strip for use in the present invention.
  • [0021]
    FIG. 3 is a hydrodynamic voltammogram illustrating the dependence of applied voltage with measured current.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0022]
    While the present invention is particularly adapted to the measurement of glucose concentration in blood, it will be apparent to those of skill in the art that the method described herein may be adapted to improve the selectivity of other systems used for the electrochemical measurement of analytes in physiological fluids. Examples of systems that may be adapted to improve selectivity using the method according to the present invention include electrochemical sensors used to measure the concentration of lactate, lactate, alcohol, cholesterol, amino acids, choline, and fructosamine in physiological fluids. Examples of physiological fluids that may contain such analytes include blood, plasma, serum, urine, and interstitial fluid. It will further be understood that, while the method of the present invention is described in an electrochemical system where the measured current is produced by oxidation, the invention would be equally applicable to a system wherein the measured current is produced by reduction.
  • [0023]
    The present invention is directed to a method for improving the selectivity of an electrochemical measuring system that is particularly adapted for use in a blood glucose measurement system. More particularly, the present invention is directed to a method for improving the selectivity of a blood glucose measurement system by partially or wholly correcting for the effect of the direct interference current. Selectivity in such systems being a measure of the ability of the system to accurately measure the glucose concentration in a sample of physiological fluid which includes one or more compounds which create an interfering current. Improvement of selectivity thus reduces the current generated at the working electrode by the presence of interfering compounds (i.e. compounds other than glucose which oxidize to generate interfering current) and makes the measured current more representative of the glucose concentration. In particular, the measured current may be a function of the oxidation of interfering compounds commonly found in physiological fluids such as, for example, acetaminophen (Tylenol™ or Paracetamol), ascorbic acid, bilirubin, dopamine, gentisic acid, glutathione, levodopa, methyldopa, tolazimide, tolbutamide and uric acid. Such interfering compounds may be oxidized by, for example, reacting chemically with the redox mediator or by oxidizing at the electrode surface.
  • [0024]
    In a perfectly selective system, there would be no oxidation current generated by any interfering compound and the entire oxidation current would be generated by oxidation of glucose. However, if oxidation of interfering compounds and the resulting oxidation current cannot be avoided the present invention describes a method of removing some or all of the effect of interfering compounds by quantifying the proportion of the overall oxidation current generated by the interfering compounds and subtracting that quantity from the overall oxidation current. In particular, in a method according to the present invention, using a test strip that includes first working electrode and second working electrode, two different potentials are applied and the oxidation current generated at each of the working electrodes is measure used to estimate the respective oxidation current proportions for both the glucose and interfering compounds.
  • [0025]
    In one embodiment of a method according to the present invention, a test strip is used which includes a sample chamber containing a first working electrode, a second working electrode, and a reference electrode. The first working electrode, the second working electrode and the reference electrodes are covered by glucose oxidase (the enzyme) and a Ferricyanide (the redox mediator). When a sample of blood (the physiological fluid) is placed in the sample chamber, the glucose oxidase is reduced by glucose in the blood sample generating gluconic acid. The gluconic acid is then oxidized by reduction of the Ferricyanide to Ferrocyanide, yielding a reduced redox mediator with a concentration proportional to the glucose concentration. An example of a test strip that may be suitable for use in a method according to the present invention is the OneTouch® Ultra® test strip sold by LifeScan, Inc. of Milpitas, Calif. Other suitable strips are described in international publication WO 01/67099A1 and WO 01/73124A2.
  • [0026]
    In one embodiment of a method according to the present invention a first potential is applied to a first working electrode and a second potential is applied to the second working electrode. In this embodiment, the first potential is selected to be in a range in which the glucose current response is relatively insensitive to the applied potential and thus the magnitude of the glucose current at the first working electrode is limited by the amount of reduced redox mediator diffusing to the first working electrode. It should be noted that glucose is not directly oxidized at a working electrode, but instead is indirectly oxidized through using a redox enzyme and a redox mediator. In the description of the present invention, the glucose current refers to an oxidation of reduced redox mediator that correlates to the glucose concentration. In an embodiment of the present invention where ferri/ferrocyanide is the redox mediator and carbon is the working electrode, the first potential may range from about 0 millivolts to about 500 millivolts, and more preferably from about 385 millivolts to about 415 millivolts, and yet even more preferably may range from about 395 to 405 mV. A second potential is applied to a second working electrode such that the second potential is greater than the first potential. Where the applied potential is greater than the potential needed to oxidize the glucose. In an embodiment of the present invention where ferri/ferrocyanide is the redox mediator and carbon is the working electrode, the second potential may range from about 50 millivolts to about 1000 millivolts, and more preferably from about 420 millivolts to about 1000 millivolts.
  • [0027]
    Because the glucose current does not increase or increases only minimally with increasing potential, the glucose current at the second working electrode should be substantially equal to the glucose current at the first working electrode, even though the potential at the second working electrode is greater than the potential at the first electrode. Thus, any additional current measured at the second working electrode may be attributed to the oxidation of interfering compounds. In other words, the higher potential at the second working electrode should cause a glucose overpotenital current to be measured at the second working electrode which is equal or substantially equal in magnitude to the glucose current at the first working electrode because the first potential and second potential are in a limiting glucose current range which is insensitive to changes in applied potential. However, in practice, other parameters may have an impact on the measured current, for example, where a higher potential is applied to the second working electrode, there is often a slight increase in the overall current at the second working electrode as a result of an IR drop or capacitive effects. When an IR drop (i.e. uncompensated resistance) is present in the system, a higher applied potential causes an increase in the measured current magnitude. Examples of IR drops may be the nominal resistance of the first working electrode, second working electrode, the reference electrode, the physiological fluid between the working electrode and the reference electrode. In addition, the application of a higher potential results in the formation of a larger ionic double layer which forms at the electrode/liquid interface, increasing the ionic capacitance and the resulting current at either the first working electrode or second working electrode.
  • [0028]
    In order to determine the actual relationship between the glucose current measured at the first working electrode and the second working electrode, it is necessary to develop a suitable equation. It should be noted that the glucose current at the second working electrode may also be referred to as a glucose overpotential current. A directly proportional relationship between the glucose current and the glucose overpotential current may be described by the following equation.
  • [0000]

    X G ×A 1G =A 2G  (eq 1)
  • [0000]
    where XG is a glucose dependent voltage effect factor, A1G is the glucose current at the first working electrode and A2G is the glucose current at the second working electrode.
  • [0029]
    In an embodiment of the present invention, where ferri/ferrocyanide is the redox mediator and carbon is the working electrode, the voltage effect factor XG for glucose may be expected to be between about 0.95 any about 1.1. In this embodiment of the invention, higher potentials do not have a significant impact on the glucose oxidation current because the redox mediator (ferrocyanide) has fast electron transfer kinetics and reversible electron transfer characteristics with the working electrode. Because the glucose current does not increase with increasing potential after a certain point, the glucose current may be said to be saturated or in a diffusion limited regime.
  • [0030]
    In the embodiment of the present invention described above, glucose is indirectly measured by oxidizing ferrocyanide at the working electrode and where the ferrocyanide concentration is directly proportional to the glucose concentration. The standard potential (Eo) value for a particular electrochemical compound is a measure of that compound's ability to exchange electrons with other chemical compounds. In the method according to the present invention, the potential at the first working electrode is selected to be greater than the standard potential (Eo) of the redox mediator. Because the first potential is selected such that it is sufficiently greater than the Eo value of the redox couple, the oxidation rate does not increase substantially as the applied potential increases. Thus, applying a greater potential at the second working electrode will not increase the oxidation at the second working electrode and any increased current measured at the higher potential electrode must be due to other factors, such as, for example, oxidation of interfering compounds.
  • [0031]
    FIG. 3 is a hydrodynamic voltammogram illustrating the dependence of applied voltage with measured current where ferri/ferrocyanide is the redox mediator and carbon is the working electrode. Each data point on the graph represents at least one experiment where a current is measured 5 seconds after applying a voltage across a working electrode and a reference electrode. FIG. 3 shows that the current forms an onset of a plateau region at about 400 mV because the applied voltage is sufficiently greater than of the Eo value of ferrocyanide. Thus, as illustrated in FIG. 3, as the potential reaches approximately 400 mV, the glucose current becomes saturated because the oxidation of ferrocyanide is diffusion limited (i.e. the diffusion of ferrocyanide to the working electrode limits the magnitude of the measured current and is not limited by the electron transfer rate between ferrocyanide and the electrode).
  • [0032]
    In general, current generated by the oxidation of interfering compounds is not saturated by increases in applied voltage and shows a much stronger dependence on applied potential than current generated by oxidation of ferrocyanide (the ferrocyanide having been generated from the interaction of glucose with the enzyme and the enzyme with ferrocyanide. Typically, interfering compounds have slower electron transfer kinetics than redox mediators (i.e. ferrocyanide). This difference is ascribed to the fact that most interfering compounds undergo an inner sphere electron transfer pathway as opposed to the faster outer sphere electron transfer pathway of ferrocyanide. A typical inner sphere electron transfer requires a chemical reaction to occur, such as a hydride transfer, before transferring an electron. In contrast, an outer sphere electron transfer does not require a chemical reaction before transferring an electron. Therefore, inner sphere electron transfer rates are typically slower than outer sphere electron transfers because they require an additional chemical reaction step. The oxidation of ascorbate to dehydroascorbate is an example of an inner sphere oxidation that requires the liberation of two hydride moieties. The oxidation of ferrocyanide to ferricyanide is an example of an outer sphere electron transfer. Therefore, the current generated by interfering compounds generally increases when testing at a higher potential.
  • [0033]
    A relationship between an interfering compound current at the first working electrode and an interfering compound overpotential current at the second working electrode can be described by the following equation,
  • [0000]

    Y×I 1 =I 2  (eq 2)
  • [0000]
    where Y is an interfering compound dependent voltage effect factor, I1 is the interfering compound current, and I2 is the interfering compound overpotential current. Because the interfering compound voltage effect factor Y is dependent upon a number of factors, including, the particular interfering compound or compounds of concern and the material used for the working electrodes, calculation of a particular interfering compound dependent voltage effect factor for a particular system, test strip, analyte and interfering compound or compounds may require experimentation to optimize the voltage effect factor for those criteria. Alternatively, under certain circumstances, appropriate voltage effect factors may be derived or described mathematically.
  • [0034]
    In an embodiment of the present invention where ferri/ferrocyanide is the redox mediator and carbon is the working electrode, the interfering compound dependent voltage effect factor Y could be mathematically described using the Tafel equation for I1 and I2,
  • [0000]
    I 1 = a exp ( η 1 b ) ( eq 2 a ) I 2 = a exp ( η 2 b ) ( eq 2 b )
  • [0000]
    where η1=E1−Eo, η2=E2−Eo, b′ is a constant depending of the specific electroactive interfering compound, E1 is the first potential, and E2 is the second potential. The value of Eo (the standard potential of a specific interfering compound) is not important because it is canceled out in the calculation of Δη. Equations 2, 2a, 2b can be combined and rearranged to yield the following equation,
  • [0000]
    Y = exp ( Δ η b ) ( eq 2 c )
  • [0000]
    where Δη=E1−E2. Equation 2c provides a mathematical relationship describing the relationship between Δη (i.e. the difference between the first potential and the second potential) and the interfering compound dependent voltage effect factor Y. In an embodiment of the present invention, Y may range from about 1 to about 100, and more preferably between about 1 and 10. In an embodiment of this invention, the interfering compound dependent voltage effect factor Y may be determined experimentally for a specific interfering compound or combination of interfering compounds. It should be noted that the interfering compound dependent voltage effect factor Y for interfering compounds is usually greater than voltage effect factor XG for glucose. As the following sections will describe, the mathematical relationship of a) the interfering compound current I1 and the interfering compound overpotential current I2; and b) the glucose current A1G and the glucose overpotential current A2G will allow a glucose algorithm to be proposed which will reduce the effects of interfering compounds for measuring glucose.
  • [0035]
    In an embodiment of the present invention, an algorithm was developed to calculate a corrected glucose current (i.e. A1G and A2G) which is independent of interferences. After dosing a sample onto a test strip, a first potential is applied to the first working electrode and a second potential is applied to the second working electrode. At the first working electrode, a first current is measured which can be described by the following equation,
  • [0000]

    W 1 =A 1G +I 1  (eq 3)
  • [0000]
    where W1 is the first current at the first working electrode. In other words, the first current includes a superposition of the glucose current A1G and the interfering compound current I1. More specifically, the interfering compound current may be a direct interfering current which has been described hereinabove. At the second working electrode, a second current is measured at the second potential or overpotential which can be described by the following equation,
  • [0000]

    W 2 =A 2G +I 2  (eq 4)
  • [0000]
    where W2 is the second current at the second working electrode, A2G is the glucose overpotential current measured at the second potential, and I2 is the interfering compound overpotential current measured at the second potential. More specifically, the interfering compound overpotential current may be a Direct Interfering compound Current which has been described hereinabove. Using the previously described 4 equations (eq's 1 to 4) which contain 4 unknowns (A1G, A2G, I1, and I2), it is now possible to calculate a corrected glucose current equation which is independent of interfering compounds.
  • [0036]
    As the first step in the derivation, A2G from eq 1 and I2 from eq 2 can be substituted into eq 4 to give the following eq 5.
  • [0000]

    W 2 =X G A 1G +YI 1  (eq 5)
  • [0037]
    Next, eq 3 is multiplied by interfering compound dependent voltage effect factor Y for interfering compounds to give eq 6.
  • [0000]

    YW 1 =YA 1G +YI 1  (eq 6)
  • [0000]
    Eq 5 can now be subtracted from eq 6 to give the following form shown in eq 7
  • [0000]

    W 2 −YW 1 =X G A 1G −YA 1G  (eq 7)
  • [0000]
    Eq 7 can now be rearranged to solve for the corrected glucose current A1G measured at the first potential as shown in eq 8.
  • [0000]
    A 1 G = W 2 - YW 1 X G - Y ( eq 8 )
  • [0000]
    Eq 8 outputs a corrected glucose current A1G which removes the effects of interferences requiring only the current output of the first working electrode and second working electrode (e.g. W1 and W2), glucose dependent voltage effect factors XG, and interfering compound dependent voltage effect factor Y for interfering compounds.
  • [0038]
    A glucose meter containing electronics is electrically interfaced with a glucose test strip to measure the current from W1 and W2. In one embodiment of the present invention, XG and Y may be programmed into the glucose meter as read only memory. In another embodiment of the present invention XG and Y may be transferred to the meter via a calibration code chip. The calibration code chip would have in its memory a particular set of values for XG and Y which would be calibrated for a particular lot of test strips. This would account for test strip lot-to-lot variations that may occur in XG and Y.
  • [0039]
    In another embodiment of the present invention, the corrected glucose current in eq 8 may be used by the meter only when a certain threshold is exceeded. For example, if W2 is about 10% or greater than W1, then the meter would use eq 8 to correct for the current output. However, if W2 is about 10% or less than W1, the interfering compound concentration is low and thus the meter can simply take an average current value between W1 and W2 to improve the accuracy and precision of the measurement. Instead of simply averaging the current of W1 and W2, a more accurate approach may be to average W1 with
  • [0000]
    W 2 X G
  • [0000]
    where the glucose dependent voltage effect factor XG is taken into account (note
  • [0000]
    W 2 X G
  • [0000]
    approximately equals A1G according to eq 1 and 4 when I2 is low). The strategy of using eq 8 only under certain situations where it is likely that a significant level of interferences are in the sample mitigates the risk of overcorrecting the measured glucose current. It should be noted that when W2 is sufficiently greater than W1 by a large amount (e.g. about 100% or more), this is an indicator of having an unusually high concentration of interferences. In such a case, it may be desirable to output an error message instead of a glucose value because a very high level of interfering compounds may cause a breakdown in the accuracy of eq 8.
  • [0040]
    The following sections will describe a possible test strip embodiment which may be used with the proposed algorithm of the present invention as shown in eq 8. FIG. 1 is an exploded perspective view of test strip 600, which includes six layers disposed upon a base substrate 5. These six layers are a conductive layer 50, an insulation layer 16, a reagent layer 22, an adhesive layer 60, a hydrophilic layer 70, and a top layer 80. Test strip 600 may be manufactured in a series of steps wherein the conductive layer 50, insulation layer 16, reagent layer 22, adhesive layer 60 are deposited on base substrate 5 using, for example, a screen printing process. Hydrophilic layer 70 and top layer 80 may be deposed from a roll stock and laminated onto base substrate 5. The fully assembled test strip forms a sample receiving chamber that can accept a blood sample so that it can be analyzed.
  • [0041]
    Conductive layer 50 includes reference electrode 10, first working electrode 12, second working electrode 14, a first contact 13, a second contact 15, a reference contact 11, and a strip detection bar 17. Suitable materials which may be used for the conductive layer are Au, Pd, Ir, Pt, Rh, stainless steel, doped tin oxide, carbon, and the like. Preferably, the material for the conductive layer may be a carbon ink such as those described in U.S. Pat. No. 5,653,918.
  • [0042]
    Insulation layer 16 includes cutout 18 which exposes a portion of reference electrode 10, first working electrode 12, and second working electrode 14 which can be wetted by a liquid sample. As a non-limiting example, insulation layer (16 or 160) may be Ercon E6110-116 Jet Black Insulayer Ink which may be purchased from Ercon, Inc.
  • [0043]
    Reagent layer 22 may be disposed on a portion of conductive layer 50 and insulation layer 16. In an embodiment of the present invention, reagent layer 22 may include chemicals such as a redox enzyme and redox mediator which selectivity react with glucose. During this reaction, a proportional amount of a reduced redox mediator can be generated that then can be measured electrochemically so that a glucose concentration can be calculated. Examples of reagent formulations or inks suitable for use in the present invention can be found in U.S. Pat. Nos. 5,708,247 and 6,046,051; published international applications WO01/67099 and WO01/73124, all of which are incorporated by reference herein.
  • [0044]
    Adhesive layer 60 includes first adhesive pad 24, second adhesive pad 26, and third adhesive pad 28. The side edges of first adhesive pad 24 and second adhesive pad 26 located adjacent to reagent layer 22 each define a wall of a sample receiving chamber. In an embodiment of the present invention, the adhesive layer may comprise a water based acrylic copolymer pressure sensitive adhesive which is commercially available from Tape Specialties LTD in Tring, Herts, United Kingdom (part#A6435).
  • [0045]
    Hydrophilic layer 70 includes a distal hydrophilic pad 32 and proximal hydrophilic pad 34. As a non-limiting example, hydrophilic layer 70 be a polyester having one hydrophilic surface such as an anti-fog coating which is commercially available from 3M. It should be noted that both distal hydrophilic film 32 and proximal hydrophilic film 34 are visibly transparent enabling a user to observe a liquid sample filling the sample receiving chamber.
  • [0046]
    Top layer 80 includes a clear portion 36 and opaque portion 38. Top layer 80 is disposed on and adhered to hydrophilic layer 70. As a non-limiting example, top layer 40 may be a polyester. It should be noted that the clear portion 36 substantially overlaps proximal hydrophilic pad 32 which allows a user to visually confirm that the sample receiving chamber is sufficiently filled. Opaque portion 38 helps the user observe a high degree of contrast between a colored fluid such as, for example, blood within the sample receiving chamber and the opaque section of the top film.
  • [0047]
    FIG. 2 is a simplified schematic showing a meter 500 interfacing with a test strip 600. Meter 500 has three electrical contacts that form an electrical connection to first working electrode 12, second working electrode 14, and reference electrode 10. In particular connector 101 connects voltage source 103 to first working electrode 12, connector 102 connects voltage source 104 to second working electrode 14 and common connector 100 connects voltage source 103 and 104 to reference electrode 10. When performing a test, voltage source 103 in meter 500 applies a first potential E1 between first working electrode 12 and reference electrode 10 and voltage source 104 applies a second potential E2 between second working electrode 14 and reference electrode 10. A sample of blood is applied such that first working electrode 12, second working electrode 14, and reference electrode 10 are covered with blood. This causes reagent layer 22 to become hydrated which generates ferrocyanide in an amount proportional to the glucose and/or interfering compound concentration present in the sample. After about 5 seconds from the sample application, meter 500 measures an oxidation current for both first working electrode 12 and second working electrode 14.
  • [0048]
    In the previously described first and second test strip embodiments, the first working electrode 12 and second working electrode 14 had the same area. It should be noted that the present invention is not limited to test strips having equal areas. For alternative embodiments to the previously described strips where the areas are different, the current output for each working electrode must be normalized for area. Because the current output is directly proportional to area, the terms within Equation 1 to Equation 8 may be in units of amperes (current) or in amperes per unit area (i.e. current density).
  • [0049]
    It will be recognized that equivalent structures may be substituted for the structures illustrated and described herein and that the described embodiment of the invention is not the only structure that may be employed to implement the claimed invention. In addition, it should be understood that every structure described above has a function and such structure can be referred to as a means for performing that function. While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to hose skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims (8)

1. A method of reducing interferences in an electrochemical sensor comprising:
applying a first potential to a first working electrode;
applying a second potential to a second working electrode, wherein said second potential is greater than the absolute value of said first potential;
measuring a first current, at said first working electrode, which comprises an analyte current and an interfering compound current;
measuring a second current, at said second working electrode, which comprises an analyte overpotential current and an interfering compound overpotential current, wherein said analyte overpotential current has a first directly proportional relationship to said analyte current and, wherein said interfering compound overpotential current has a second directly proportional relationship to said interfering compound current; and
calculating a corrected current value representative of an analyte concentration using an equation which is a function of said first current, said second current, said first directly proportional relationship, and said second directly proportional relationship.
2. The method of claim 1, wherein said equation is
A 1 = W 2 - YW 1 X - Y
where A1 is said analyte current, W1 is said first current, W2 is said second current, X is an analyte voltage effect factor, and Y is an interfering compound voltage effect factor.
3. The method of claim 1, wherein said analyte is glucose.
4. The method of claim 1, wherein said first potential is between about 385 millivolts and about 415 millivolts for said electrochemical sensor which comprises a carbon working electrode and a ferrocyanide redox mediator.
5. The method of claim 1, wherein said second potential is between about 420 millivolts and about 1000 millivolts for said electrochemical sensor which comprises a carbon working electrode and a ferrocyanide redox mediator.
6. The method of claim 1, wherein said interfering compound current results from the oxidation of at least one chemical chosen from the group consisting of acetaminophen, ascorbic acid, bilirubin, dopamine, gentisic acid, glutathione, levodopa, methyldopa, tolazimide, tolbutamide, and uric acid.
7. (canceled)
8. (canceled)
US12574469 2003-10-31 2009-10-06 Method of reducing interferences in an electrochemical sensor using two different applied potentials Abandoned US20100018878A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US51625203 true 2003-10-31 2003-10-31
US55872804 true 2004-03-31 2004-03-31
US55842404 true 2004-03-31 2004-03-31
US10977154 US7618522B2 (en) 2003-10-31 2004-10-29 Method of reducing interferences in an electrochemical sensor using two different applied potentials
US12574469 US20100018878A1 (en) 2003-10-31 2009-10-06 Method of reducing interferences in an electrochemical sensor using two different applied potentials

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12574469 US20100018878A1 (en) 2003-10-31 2009-10-06 Method of reducing interferences in an electrochemical sensor using two different applied potentials

Publications (1)

Publication Number Publication Date
US20100018878A1 true true US20100018878A1 (en) 2010-01-28

Family

ID=34577659

Family Applications (7)

Application Number Title Priority Date Filing Date
US10577586 Active 2024-12-30 US7653492B2 (en) 2003-10-31 2004-10-29 Method of reducing the effect of direct interference current in an electrochemical test strip
US10977316 Abandoned US20050139469A1 (en) 2003-10-31 2004-10-29 Electrochemical test strip for reducing the effect of direct and mediated interference current
US10977086 Abandoned US20050139489A1 (en) 2003-10-31 2004-10-29 Method of reducing the effect of direct and mediated interference current in an electrochemical test strip
US10977292 Abandoned US20050114062A1 (en) 2003-10-31 2004-10-29 Method of reducing the effect of direct interference current in an electrochemical test strip
US10976489 Abandoned US20050133368A1 (en) 2003-10-31 2004-10-29 Electrochemical test strip for reducing the effect of direct interference current
US10977154 Active 2027-03-23 US7618522B2 (en) 2003-10-31 2004-10-29 Method of reducing interferences in an electrochemical sensor using two different applied potentials
US12574469 Abandoned US20100018878A1 (en) 2003-10-31 2009-10-06 Method of reducing interferences in an electrochemical sensor using two different applied potentials

Family Applications Before (6)

Application Number Title Priority Date Filing Date
US10577586 Active 2024-12-30 US7653492B2 (en) 2003-10-31 2004-10-29 Method of reducing the effect of direct interference current in an electrochemical test strip
US10977316 Abandoned US20050139469A1 (en) 2003-10-31 2004-10-29 Electrochemical test strip for reducing the effect of direct and mediated interference current
US10977086 Abandoned US20050139489A1 (en) 2003-10-31 2004-10-29 Method of reducing the effect of direct and mediated interference current in an electrochemical test strip
US10977292 Abandoned US20050114062A1 (en) 2003-10-31 2004-10-29 Method of reducing the effect of direct interference current in an electrochemical test strip
US10976489 Abandoned US20050133368A1 (en) 2003-10-31 2004-10-29 Electrochemical test strip for reducing the effect of direct interference current
US10977154 Active 2027-03-23 US7618522B2 (en) 2003-10-31 2004-10-29 Method of reducing interferences in an electrochemical sensor using two different applied potentials

Country Status (9)

Country Link
US (7) US7653492B2 (en)
JP (6) JP2007514931A (en)
KR (4) KR101179998B1 (en)
CA (6) CA2543961A1 (en)
DE (4) DE602004006148T2 (en)
DK (3) DK1685393T3 (en)
EP (6) EP1685393B1 (en)
ES (4) ES2282898T3 (en)
WO (6) WO2005045416A1 (en)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060195130A1 (en) * 2001-06-12 2006-08-31 Dominique Freeman Tissue penetration device
US20090054811A1 (en) * 2004-12-30 2009-02-26 Dirk Boecker Method and apparatus for analyte measurement test time
US20090192411A1 (en) * 2002-04-19 2009-07-30 Dominique Freeman Method and apparatus for penetrating tissue
US20100327886A1 (en) * 2008-03-27 2010-12-30 Toshifumi Nakamura Measurement device, measurement system, and concentration measurement method
US7875047B2 (en) 2002-04-19 2011-01-25 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7901365B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909774B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909775B2 (en) 2001-06-12 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909777B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7914465B2 (en) 2002-04-19 2011-03-29 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7988645B2 (en) 2001-06-12 2011-08-02 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US8007446B2 (en) 2002-04-19 2011-08-30 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8062231B2 (en) 2002-04-19 2011-11-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8079960B2 (en) 2002-04-19 2011-12-20 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US8197421B2 (en) 2002-04-19 2012-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8251921B2 (en) 2003-06-06 2012-08-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US8262614B2 (en) 2003-05-30 2012-09-11 Pelikan Technologies, Inc. Method and apparatus for fluid injection
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US8296918B2 (en) 2003-12-31 2012-10-30 Sanofi-Aventis Deutschland Gmbh Method of manufacturing a fluid sampling device with improved analyte detecting member configuration
US8333710B2 (en) 2002-04-19 2012-12-18 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8372016B2 (en) 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US8382682B2 (en) 2002-04-19 2013-02-26 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8435190B2 (en) 2002-04-19 2013-05-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8439872B2 (en) 1998-03-30 2013-05-14 Sanofi-Aventis Deutschland Gmbh Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US8668656B2 (en) 2003-12-31 2014-03-11 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8721671B2 (en) 2001-06-12 2014-05-13 Sanofi-Aventis Deutschland Gmbh Electric lancet actuator
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9144401B2 (en) 2003-06-11 2015-09-29 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3394262B2 (en) 1997-02-06 2003-04-07 イー.ヘラー アンド カンパニー Small volume in vitro analyte sensor
US6862465B2 (en) 1997-03-04 2005-03-01 Dexcom, Inc. Device and method for determining analyte levels
US8527026B2 (en) 1997-03-04 2013-09-03 Dexcom, Inc. Device and method for determining analyte levels
US9757061B2 (en) 2006-01-17 2017-09-12 Dexcom, Inc. Low oxygen in vivo analyte sensor
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US7899511B2 (en) 1997-03-04 2011-03-01 Dexcom, Inc. Low oxygen in vivo analyte sensor
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7310543B2 (en) * 2001-03-26 2007-12-18 Kumetrix, Inc. Silicon microprobe with integrated biosensor
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
DE10134650B4 (en) * 2001-07-20 2009-12-03 Roche Diagnostics Gmbh System for withdrawing small amounts of body fluid
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US7761130B2 (en) 2003-07-25 2010-07-20 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US7828728B2 (en) 2003-07-25 2010-11-09 Dexcom, Inc. Analyte sensor
US7767068B2 (en) * 2002-12-02 2010-08-03 Epocal Inc. Heterogeneous membrane electrodes
US7842234B2 (en) * 2002-12-02 2010-11-30 Epocal Inc. Diagnostic devices incorporating fluidics and methods of manufacture
US8052926B2 (en) * 2002-12-27 2011-11-08 Roche Diagnostics Operations, Inc. Method for manufacturing a sterilized lancet integrated biosensor
US7134999B2 (en) 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US20100185071A1 (en) * 2003-12-05 2010-07-22 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
WO2005011520A3 (en) 2003-07-25 2005-12-15 Dexcom Inc Oxygen enhancing membrane systems for implantable devices
EP2069772B1 (en) * 2006-10-04 2014-05-21 DexCom, Inc. Dual electrode system for a continuous analyte sensor
US7933639B2 (en) 2003-08-01 2011-04-26 Dexcom, Inc. System and methods for processing analyte sensor data
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US7778680B2 (en) 2003-08-01 2010-08-17 Dexcom, Inc. System and methods for processing analyte sensor data
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US20100168542A1 (en) 2003-08-01 2010-07-01 Dexcom, Inc. System and methods for processing analyte sensor data
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US8886272B2 (en) 2004-07-13 2014-11-11 Dexcom, Inc. Analyte sensor
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8233959B2 (en) 2003-08-22 2012-07-31 Dexcom, Inc. Systems and methods for processing analyte sensor data
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
ES2282898T3 (en) * 2003-10-31 2007-10-16 Lifescan Scotland Ltd Electrochemical test strip to reduce the effect of the direct interference current.
US7655119B2 (en) * 2003-10-31 2010-02-02 Lifescan Scotland Limited Meter for use in an improved method of reducing interferences in an electrochemical sensor using two different applied potentials
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7460898B2 (en) * 2003-12-05 2008-12-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7366556B2 (en) * 2003-12-05 2008-04-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7467003B2 (en) * 2003-12-05 2008-12-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP2239567B1 (en) 2003-12-05 2015-09-02 DexCom, Inc. Calibration techniques for a continuous analyte sensor
US7424318B2 (en) * 2003-12-05 2008-09-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7831287B2 (en) 2006-10-04 2010-11-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP1711791B1 (en) 2003-12-09 2014-10-15 DexCom, Inc. Signal processing for continuous analyte sensor
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8277713B2 (en) 2004-05-03 2012-10-02 Dexcom, Inc. Implantable analyte sensor
US20050245799A1 (en) * 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US8792955B2 (en) 2004-05-03 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
US20060016700A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US7946984B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
US20080242961A1 (en) * 2004-07-13 2008-10-02 Dexcom, Inc. Transcutaneous analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US7935063B2 (en) * 2005-03-02 2011-05-03 Roche Diagnostics Operations, Inc. System and method for breaking a sterility seal to engage a lancet
US7815579B2 (en) * 2005-03-02 2010-10-19 Roche Diagnostics Operations, Inc. Dynamic integrated lancing test strip with sterility cover
RU2422534C2 (en) * 2005-03-04 2011-06-27 Байер Хелткэр Ллк Enzyme stabilisation in electrochemical biosensors
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
WO2007019395A1 (en) 2005-08-05 2007-02-15 Bayer Healthcare Llc Method for distinguishing electrochemical sensors
WO2007022485A3 (en) * 2005-08-19 2007-11-15 Javier Alarcon Sterilization of biosensors
DK2260757T3 (en) * 2005-09-09 2016-06-27 F Hoffmann-La Roche Ag System tools, apparatus and a program for diabetes treatment
WO2007059455A3 (en) * 2005-11-10 2008-01-31 Univ Virginia Commonwealth Non-biofouling, universal redox electrode and measurement system
WO2007075936A3 (en) * 2005-12-27 2007-08-23 Bayer Healthcare Llc Process of making electrodes for test sensors
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
US8163162B2 (en) * 2006-03-31 2012-04-24 Lifescan, Inc. Methods and apparatus for analyzing a sample in the presence of interferents
US7909983B2 (en) * 2006-05-04 2011-03-22 Nipro Diagnostics, Inc. System and methods for automatically recognizing a control solution
RU2475731C2 (en) * 2006-05-08 2013-02-20 Байер Хэлткэр Ллк Low sample volume electrochemical test sensor
US20080071157A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
DE102006043718B4 (en) * 2006-09-18 2014-12-31 Alexander Adlassnig Determination of hydrogen peroxide concentrations
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
EP2437056B1 (en) 2006-10-05 2013-11-20 Lifescan Scotland Ltd Methods for determining the presence of a sufficient quantity of fluid sample on a test strip
ES2375288T3 (en) 2006-10-05 2012-02-28 Lifescan Scotland Limited Procedure for determining analyte concentrations hematocrit corrected.
US9046480B2 (en) 2006-10-05 2015-06-02 Lifescan Scotland Limited Method for determining hematocrit corrected analyte concentrations
ES2544353T3 (en) 2006-10-05 2015-08-28 Lifescan Scotland Ltd Methods for determining an analyte concentration using signal processing algorithms
GB0621352D0 (en) * 2006-10-27 2006-12-06 Suresensors Measurement device
JP2008129004A (en) * 2006-11-24 2008-06-05 Health & Life Co Ltd Biosensor test strip
EP2147304B1 (en) * 2007-04-27 2015-10-14 Abbott Diabetes Care Inc. No calibration analyte sensors and methods
US8709709B2 (en) 2007-05-18 2014-04-29 Luoxis Diagnostics, Inc. Measurement and uses of oxidative status
WO2008144481A1 (en) 2007-05-18 2008-11-27 Institute For Molecular Medicine, Inc. Measurement and uses of oxidative status
EP2152350A4 (en) 2007-06-08 2013-03-27 Dexcom Inc Integrated medicament delivery device for use with continuous analyte sensor
US8236154B2 (en) * 2007-07-05 2012-08-07 Apex Biotechnology Corp. Composite modified electrode strip
EP2176651B1 (en) * 2007-07-26 2015-09-09 Agamatrix, Inc. Electrochemical test strips
US20090076360A1 (en) 2007-09-13 2009-03-19 Dexcom, Inc. Transcutaneous analyte sensor
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
US9135402B2 (en) * 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
USD612279S1 (en) 2008-01-18 2010-03-23 Lifescan Scotland Limited User interface in an analyte meter
CA2715628A1 (en) * 2008-02-21 2009-08-27 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
CA2659142C (en) 2008-03-21 2017-10-03 Lifescan Scotland Limited Analyte testing method and system
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
WO2009121026A1 (en) * 2008-03-28 2009-10-01 Dexcom, Inc. Polymer membranes for continuous analyte sensors
USD611151S1 (en) 2008-06-10 2010-03-02 Lifescan Scotland, Ltd. Test meter
USD611372S1 (en) 2008-09-19 2010-03-09 Lifescan Scotland Limited Analyte test meter
WO2010033724A3 (en) 2008-09-19 2010-05-20 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US8956308B2 (en) 2008-09-29 2015-02-17 Bayer Healthcare Llc Integrated-testing system
US8012428B2 (en) * 2008-10-30 2011-09-06 Lifescan Scotland, Ltd. Analytical test strip with minimal fill-error sample viewing window
KR100918027B1 (en) * 2009-02-19 2009-09-18 주식회사 올메디쿠스 Bio-sensor provided with code electrode, method for manufacturing the same, and method for taking sensor information from the same
WO2010111660A1 (en) 2009-03-27 2010-09-30 Dexcom, Inc. Methods and systems for promoting glucose management
US20110048972A1 (en) * 2009-08-31 2011-03-03 Lifescan Scotland Limited Multi-analyte test strip with shared counter/reference electrode and inline electrode configuration
JP5352670B2 (en) * 2009-08-31 2013-11-27 パナソニック株式会社 Sensor and method for measuring the concentration
KR101109857B1 (en) * 2009-09-29 2012-02-14 광운대학교 산학협력단 Electrochemical Biosensor Using Double Pulse Excitation
US8936713B2 (en) * 2009-12-11 2015-01-20 Lifescan Scotland Limited Fill sufficiency method and system
GB201005357D0 (en) 2010-03-30 2010-05-12 Menai Medical Technologies Ltd Sampling plate
GB201005359D0 (en) 2010-03-30 2010-05-12 Menai Medical Technologies Ltd Sampling plate
US20120238841A1 (en) * 2010-04-15 2012-09-20 Mark Castle Sample capture in one step for test strips
JP5753720B2 (en) * 2010-04-22 2015-07-22 アークレイ株式会社 Biosensor
JP5925285B2 (en) * 2010-04-22 2016-05-25 アークレイ株式会社 Biosensor
GB201007711D0 (en) * 2010-05-07 2010-06-23 Pa Consulting Services Devices and methods for testing analytes
US8940141B2 (en) 2010-05-19 2015-01-27 Lifescan Scotland Limited Analytical test strip with an electrode having electrochemically active and inert areas of a predetermined size and distribution
US20110290668A1 (en) * 2010-05-27 2011-12-01 Lifescan Scotland Limited Analytical test strip with crossroads exposed electrode configuration
EP2601518A4 (en) * 2010-08-06 2017-01-18 Schlumberger Technology Bv Electrochemical sensor
US20120048746A1 (en) * 2010-08-30 2012-03-01 Cilag Gmbh International Analyte test strip with electrically distinguishable divided electrode
RU2602170C2 (en) 2010-09-13 2016-11-10 Лайфскэн Скотлэнд Лимитед Method of measuring analyte and system with hematocrit compensation
EP2659268A4 (en) * 2010-12-31 2017-01-18 Cilag Gmbh Int Systems and methods for high accuracy analyte measurement
WO2012118784A1 (en) 2011-02-28 2012-09-07 Institute For Molecular Medicine, Inc. Method and apparatus for measuring oxidation-reduction potential
WO2012133633A1 (en) * 2011-03-29 2012-10-04 株式会社テクノメデイカ Disposable lysine sensor
CN102866196B (en) * 2011-07-06 2014-09-17 华广生技股份有限公司 Method for operating a measurement for a sample on an electrochemical test strip
US8936199B2 (en) 2012-04-13 2015-01-20 Blackberry Limited UICC apparatus and related methods
USD703208S1 (en) * 2012-04-13 2014-04-22 Blackberry Limited UICC apparatus
KR20150013146A (en) 2012-04-19 2015-02-04 로익스 다이어그노스틱스, 아이엔씨. Multiple layer gel
USD701864S1 (en) * 2012-04-23 2014-04-01 Blackberry Limited UICC apparatus
JP2013242171A (en) * 2012-05-18 2013-12-05 Tanita Corp Concentration measuring apparatus
CA2817591C (en) 2012-06-08 2016-05-03 Hmd Biomedical Inc. Test strip and detecting device
US20130341207A1 (en) * 2012-06-21 2013-12-26 Lifescan Scotland Limited Analytical test strip with capillary sample-receiving chambers separated by stop junctions
US9128038B2 (en) * 2012-06-21 2015-09-08 Lifescan Scotland Limited Analytical test strip with capillary sample-receiving chambers separated by a physical barrier island
US8877023B2 (en) * 2012-06-21 2014-11-04 Lifescan Scotland Limited Electrochemical-based analytical test strip with intersecting sample-receiving chambers
GB2505694B (en) * 2012-09-07 2017-03-22 Lifescan Scotland Ltd Electrochemical-based analytical test strip with bare interferent electrodes
US9360446B2 (en) 2012-10-23 2016-06-07 Aytu Bioscience, Inc. Methods and systems for measuring and using the oxidation-reduction potential of a biological sample
US9244036B2 (en) 2012-11-16 2016-01-26 Cilag Gmbh International System and method for determination of a concentration of at least one interfering substance and correction of glucose concentration based on the concentration of the interfering substance
CN103983669B (en) 2013-02-08 2016-08-31 昀尚有限公司 Test strip, the detection device and detection method
US9121050B2 (en) 2013-03-15 2015-09-01 American Sterilizer Company Non-enzyme based detection method for electronic monitoring of biological indicator
US8858884B2 (en) 2013-03-15 2014-10-14 American Sterilizer Company Coupled enzyme-based method for electronic monitoring of biological indicator
JP5813171B2 (en) 2013-05-02 2015-11-17 アークレイ株式会社 Analysis tool, a method of manufacturing the same, and the measuring device using the same
GB2514846B (en) * 2013-06-07 2015-09-30 Lifescan Scotland Ltd Electrochemical-based analytical test strip with a soluble electrochemically-active coating opposite a bare electrode
GB2518165B (en) * 2013-09-11 2016-04-27 Cilag Gmbh Int Electrochemical-based analytical test strip with ultra-thin discontinuous metal layer
US20150068893A1 (en) * 2013-09-12 2015-03-12 Joinsoon Medical Technology Co., Ltd. Biosensor test strip for biosensor test device
JP2015111115A (en) * 2013-11-08 2015-06-18 アークレイ株式会社 Measurement apparatus and measurement method
US20150176049A1 (en) * 2013-12-23 2015-06-25 Cilag Gmbh International Determining usability of analytical test strip
JP2017525966A (en) * 2014-08-25 2017-09-07 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 2 electrode test strip interference compensated
CN107250792A (en) * 2014-12-31 2017-10-13 三伟达保健公司 Interference with a corrected glucose test strips
EP3220137A1 (en) 2016-03-14 2017-09-20 Roche Diabetes Care GmbH Method for detecting an interferent contribution in a biosensor

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233031A (en) * 1978-12-11 1980-11-11 Environmental Sciences Associates, Inc. Electrochemical testing system and method
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4655880A (en) * 1983-08-01 1987-04-07 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
US5298146A (en) * 1991-11-08 1994-03-29 Bayer Aktiengesellschaft Device for the simultaneous detection of dissimilar gas components
US5354447A (en) * 1991-12-12 1994-10-11 Kyoto Daiichi Kagaku Co., Ltd. Biosensor and method of quantitative analysis using the same
US5582697A (en) * 1995-03-17 1996-12-10 Matsushita Electric Industrial Co., Ltd. Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same
US5628890A (en) * 1995-09-27 1997-05-13 Medisense, Inc. Electrochemical sensor
US5650062A (en) * 1995-03-17 1997-07-22 Matsushita Electric Industrial Co., Ltd. Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same
US5653918A (en) * 1996-01-11 1997-08-05 E. I. Du Pont De Nemours And Company Flexible thick film conductor composition
US5708247A (en) * 1996-02-14 1998-01-13 Selfcare, Inc. Disposable glucose test strips, and methods and compositions for making same
US5830343A (en) * 1994-07-11 1998-11-03 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Electrochemical analysis process
US5985116A (en) * 1996-12-24 1999-11-16 Matsushita Electric Industrial Co., Ltd. Biosensor
US6046051A (en) * 1997-06-27 2000-04-04 Hemosense, Inc. Method and device for measuring blood coagulation or lysis by viscosity changes
US6212417B1 (en) * 1998-08-26 2001-04-03 Matsushita Electric Industrial Co., Ltd. Biosensor
US6258229B1 (en) * 1999-06-02 2001-07-10 Handani Winarta Disposable sub-microliter volume sensor and method of making
US6287451B1 (en) * 1999-06-02 2001-09-11 Handani Winarta Disposable sensor and method of making
US6340428B1 (en) * 1998-04-02 2002-01-22 Matsushita Electric Industrial Co., Inc. Device and method for determining the concentration of a substrate
US20020020632A1 (en) * 1997-09-30 2002-02-21 Douglas Joel S. Membrane based electrochemical test device and related methods
US20020092612A1 (en) * 2000-03-28 2002-07-18 Davies Oliver William Hardwicke Rapid response glucose sensor
US20020157947A1 (en) * 2001-03-23 2002-10-31 Craig Rappin Electrochemical sensor and method thereof
US20020168290A1 (en) * 2002-05-09 2002-11-14 Yuzhakov Vadim V. Physiological sample collection devices and methods of using the same
US6540891B1 (en) * 1998-05-08 2003-04-01 Abbott Laboratories Test strip
US6599406B1 (en) * 1997-07-22 2003-07-29 Kyoto Daiichi Kagaku Co., Ltd. Concentration measuring apparatus, test strip for the concentration measuring apparatus, biosensor system and method for forming terminal on the test strip
US6730200B1 (en) * 1999-06-18 2004-05-04 Abbott Laboratories Electrochemical sensor for analysis of liquid samples
US20040120848A1 (en) * 2002-12-20 2004-06-24 Maria Teodorczyk Method for manufacturing a sterilized and calibrated biosensor-based medical device
US20040149578A1 (en) * 2003-01-30 2004-08-05 Chun-Mu Huang Method for manufacturing electrochemical sensor and structure thereof
USRE38681E1 (en) * 1997-03-25 2005-01-04 Cygnus, Inc. Electrode with improved signal to noise ratio
US6881322B2 (en) * 2000-01-25 2005-04-19 Matsushita Electric Industrial Co., Ltd. Measuring device using biosensor and biosenor used for it, and dedicated standard liquid
US20050114062A1 (en) * 2003-10-31 2005-05-26 Davies Oliver W.H. Method of reducing the effect of direct interference current in an electrochemical test strip
US7132041B2 (en) * 2003-02-11 2006-11-07 Bayer Healthcare Llc Methods of determining the concentration of an analyte in a fluid test sample

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565062A (en) * 1896-08-04 Samuel l
JPS613048A (en) * 1984-06-18 1986-01-09 Matsushita Electric Works Ltd Measurement using biosensor
EP0331696A1 (en) 1987-08-28 1989-09-13 HARMAN, John N. III Noise reduction technique for electrochemical cells
DE68924026D1 (en) * 1988-03-31 1995-10-05 Matsushita Electric Ind Co Ltd Biosensor and its production.
FR2661548B1 (en) * 1990-04-30 1992-07-17 Telemecanique The reversing contactor apparatus has locking.
JPH04240558A (en) * 1991-01-25 1992-08-27 Sumitomo Metal Ind Ltd Enzyme electrode
JP2960265B2 (en) * 1991-10-18 1999-10-06 松下電器産業株式会社 Biosensor and the measuring method using the same
JP2658769B2 (en) * 1991-10-21 1997-09-30 松下電器産業株式会社 Biosensor
CA2103325C (en) * 1992-11-23 2004-07-20 Kirk W. Johnson Techniques to improve the performance of electrochemical sensors
US5592551A (en) * 1992-12-01 1997-01-07 Scientific-Atlanta, Inc. Method and apparatus for providing interactive electronic programming guide
JPH09129236A (en) * 1995-08-25 1997-05-16 Furukawa Battery Co Ltd:The Negative active material for lithium secondary battery and lithium secondary battery
US5650052A (en) * 1995-10-04 1997-07-22 Edelstein; Sergio Variable cell size collimator
DE19781229T1 (en) * 1996-06-17 1999-01-28 Mercury Diagnostics Inc The electrochemical test device and related method
EP0836944A3 (en) * 1996-10-16 1998-12-16 Samsung Electronics Co., Ltd. Ink-jet printing using dielectric migration force
US5943263A (en) * 1997-01-08 1999-08-24 Micron Technology, Inc. Apparatus and method for programming voltage protection in a non-volatile memory system
JP3394262B2 (en) * 1997-02-06 2003-04-07 イー.ヘラー アンド カンパニー Small volume in vitro analyte sensor
US6045051A (en) * 1997-03-20 2000-04-04 Wahler Metalurgica Ltda. Integrated thermostat
JP2001516038A (en) 1997-09-05 2001-09-25 アボット・ラボラトリーズ Electrochemical sensor having an equal electrode area
JP3267907B2 (en) * 1997-09-29 2002-03-25 松下電器産業株式会社 Biosensor and method for the determination of substrates using the same
JP3267933B2 (en) * 1998-01-27 2002-03-25 松下電器産業株式会社 Determination of the substrate
WO2000013099A9 (en) 1998-08-31 2001-12-13 Cubus Corp Computer product for networking a document development system using message headers associated with message files
US6338790B1 (en) * 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
JP3462401B2 (en) * 1998-10-15 2003-11-05 日本電信電話株式会社 Electrochemical detector
JP5073129B2 (en) * 1999-03-31 2012-11-14 株式会社日本触媒 (Meth) method for purifying acrylic acid
US6616819B1 (en) * 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
US6875327B1 (en) * 1999-11-15 2005-04-05 Matsushita Electric Industrial Co., Ltd. Biosensor, method of forming thin-film electrode, and method and apparatus for quantitative determination
GB0005564D0 (en) 2000-03-08 2000-05-03 Inverness Medical Ltd Measurjement of substances in liquid
ES2312719T3 (en) 2000-03-28 2009-03-01 Diabetes Diagnostics, Inc. Glucose meter with fast response sensor.
JP2002055076A (en) * 2000-09-08 2002-02-20 Nec Corp Electrochemical sensor
GB0030929D0 (en) 2000-12-19 2001-01-31 Inverness Medical Ltd Analyte measurement
JP3972063B2 (en) * 2001-01-17 2007-09-05 アークレイ株式会社 Quantitative analysis method and quantitative analysis apparatus using sensors
EP1398626A4 (en) * 2001-06-14 2004-09-22 Matsushita Electric Ind Co Ltd Biosensor
US6837976B2 (en) * 2002-04-19 2005-01-04 Nova Biomedical Corporation Disposable sensor with enhanced sample port inlet
DE10218828A1 (en) 2002-04-26 2003-11-06 Siemens Ag Mobile RF device with transmission power limitation, can be set to maximum transmission power via mobilephone menu with user personally selecting maximum acceptable radiative loading level
KR100485671B1 (en) 2002-09-30 2005-04-27 주식회사 인포피아 A measuring instrument for biosensor
JP4642472B2 (en) 2002-10-30 2011-03-02 ライフスキャン・スコットランド・リミテッド Humidification of the enzyme print in a continuous process for manufacturing electrochemical sensors
US7462265B2 (en) * 2003-06-06 2008-12-09 Lifescan, Inc. Reduced volume electrochemical sensor
US7655119B2 (en) * 2003-10-31 2010-02-02 Lifescan Scotland Limited Meter for use in an improved method of reducing interferences in an electrochemical sensor using two different applied potentials
US7875461B2 (en) * 2007-07-24 2011-01-25 Lifescan Scotland Limited Test strip and connector

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233031A (en) * 1978-12-11 1980-11-11 Environmental Sciences Associates, Inc. Electrochemical testing system and method
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
US4655880A (en) * 1983-08-01 1987-04-07 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
US5298146A (en) * 1991-11-08 1994-03-29 Bayer Aktiengesellschaft Device for the simultaneous detection of dissimilar gas components
US5354447A (en) * 1991-12-12 1994-10-11 Kyoto Daiichi Kagaku Co., Ltd. Biosensor and method of quantitative analysis using the same
US5830343A (en) * 1994-07-11 1998-11-03 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Electrochemical analysis process
US5582697A (en) * 1995-03-17 1996-12-10 Matsushita Electric Industrial Co., Ltd. Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same
US5650062A (en) * 1995-03-17 1997-07-22 Matsushita Electric Industrial Co., Ltd. Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same
US5628890A (en) * 1995-09-27 1997-05-13 Medisense, Inc. Electrochemical sensor
US5653918A (en) * 1996-01-11 1997-08-05 E. I. Du Pont De Nemours And Company Flexible thick film conductor composition
US5708247A (en) * 1996-02-14 1998-01-13 Selfcare, Inc. Disposable glucose test strips, and methods and compositions for making same
US5985116A (en) * 1996-12-24 1999-11-16 Matsushita Electric Industrial Co., Ltd. Biosensor
USRE38681E1 (en) * 1997-03-25 2005-01-04 Cygnus, Inc. Electrode with improved signal to noise ratio
US6046051A (en) * 1997-06-27 2000-04-04 Hemosense, Inc. Method and device for measuring blood coagulation or lysis by viscosity changes
US6599406B1 (en) * 1997-07-22 2003-07-29 Kyoto Daiichi Kagaku Co., Ltd. Concentration measuring apparatus, test strip for the concentration measuring apparatus, biosensor system and method for forming terminal on the test strip
US20020020632A1 (en) * 1997-09-30 2002-02-21 Douglas Joel S. Membrane based electrochemical test device and related methods
US6340428B1 (en) * 1998-04-02 2002-01-22 Matsushita Electric Industrial Co., Inc. Device and method for determining the concentration of a substrate
US6790327B2 (en) * 1998-04-02 2004-09-14 Matsushita Electric Industrial Co., Ltd. Device and method for determining the concentration of a substrate
US6540891B1 (en) * 1998-05-08 2003-04-01 Abbott Laboratories Test strip
US6212417B1 (en) * 1998-08-26 2001-04-03 Matsushita Electric Industrial Co., Ltd. Biosensor
US6287451B1 (en) * 1999-06-02 2001-09-11 Handani Winarta Disposable sensor and method of making
US6258229B1 (en) * 1999-06-02 2001-07-10 Handani Winarta Disposable sub-microliter volume sensor and method of making
US6730200B1 (en) * 1999-06-18 2004-05-04 Abbott Laboratories Electrochemical sensor for analysis of liquid samples
US6881322B2 (en) * 2000-01-25 2005-04-19 Matsushita Electric Industrial Co., Ltd. Measuring device using biosensor and biosenor used for it, and dedicated standard liquid
US20020092612A1 (en) * 2000-03-28 2002-07-18 Davies Oliver William Hardwicke Rapid response glucose sensor
US20020157947A1 (en) * 2001-03-23 2002-10-31 Craig Rappin Electrochemical sensor and method thereof
US20030143113A2 (en) * 2002-05-09 2003-07-31 Lifescan, Inc. Physiological sample collection devices and methods of using the same
US20020168290A1 (en) * 2002-05-09 2002-11-14 Yuzhakov Vadim V. Physiological sample collection devices and methods of using the same
US20040120848A1 (en) * 2002-12-20 2004-06-24 Maria Teodorczyk Method for manufacturing a sterilized and calibrated biosensor-based medical device
US20040149578A1 (en) * 2003-01-30 2004-08-05 Chun-Mu Huang Method for manufacturing electrochemical sensor and structure thereof
US7132041B2 (en) * 2003-02-11 2006-11-07 Bayer Healthcare Llc Methods of determining the concentration of an analyte in a fluid test sample
US20050114062A1 (en) * 2003-10-31 2005-05-26 Davies Oliver W.H. Method of reducing the effect of direct interference current in an electrochemical test strip
US20050139469A1 (en) * 2003-10-31 2005-06-30 Davies Oliver W.H. Electrochemical test strip for reducing the effect of direct and mediated interference current
US20050139489A1 (en) * 2003-10-31 2005-06-30 Davies Oliver William H. Method of reducing the effect of direct and mediated interference current in an electrochemical test strip

Cited By (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8439872B2 (en) 1998-03-30 2013-05-14 Sanofi-Aventis Deutschland Gmbh Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US8206319B2 (en) 2001-06-12 2012-06-26 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8845550B2 (en) 2001-06-12 2014-09-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8721671B2 (en) 2001-06-12 2014-05-13 Sanofi-Aventis Deutschland Gmbh Electric lancet actuator
US8679033B2 (en) 2001-06-12 2014-03-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9802007B2 (en) 2001-06-12 2017-10-31 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8622930B2 (en) 2001-06-12 2014-01-07 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7909775B2 (en) 2001-06-12 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US20070043386A1 (en) * 2001-06-12 2007-02-22 Dominique Freeman Tissue penetration device
US8162853B2 (en) 2001-06-12 2012-04-24 Pelikan Technologies, Inc. Tissue penetration device
US8382683B2 (en) 2001-06-12 2013-02-26 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US20060195130A1 (en) * 2001-06-12 2006-08-31 Dominique Freeman Tissue penetration device
US8360991B2 (en) 2001-06-12 2013-01-29 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8343075B2 (en) 2001-06-12 2013-01-01 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7981055B2 (en) 2001-06-12 2011-07-19 Pelikan Technologies, Inc. Tissue penetration device
US8337421B2 (en) 2001-06-12 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8641643B2 (en) 2001-06-12 2014-02-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US7988645B2 (en) 2001-06-12 2011-08-02 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US8282577B2 (en) 2001-06-12 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US8016774B2 (en) 2001-06-12 2011-09-13 Pelikan Technologies, Inc. Tissue penetration device
US8211037B2 (en) 2001-06-12 2012-07-03 Pelikan Technologies, Inc. Tissue penetration device
US9694144B2 (en) 2001-06-12 2017-07-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US8123700B2 (en) 2001-06-12 2012-02-28 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US8216154B2 (en) 2001-06-12 2012-07-10 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8206317B2 (en) 2001-06-12 2012-06-26 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9560993B2 (en) 2001-11-21 2017-02-07 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9072842B2 (en) 2002-04-19 2015-07-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8202231B2 (en) 2002-04-19 2012-06-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8197421B2 (en) 2002-04-19 2012-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8197423B2 (en) 2002-04-19 2012-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7938787B2 (en) 2002-04-19 2011-05-10 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8157748B2 (en) 2002-04-19 2012-04-17 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8235915B2 (en) 2002-04-19 2012-08-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9724021B2 (en) 2002-04-19 2017-08-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8079960B2 (en) 2002-04-19 2011-12-20 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US8062231B2 (en) 2002-04-19 2011-11-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8007446B2 (en) 2002-04-19 2011-08-30 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9498160B2 (en) 2002-04-19 2016-11-22 Sanofi-Aventis Deutschland Gmbh Method for penetrating tissue
US7988644B2 (en) 2002-04-19 2011-08-02 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8337420B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7959582B2 (en) 2002-04-19 2011-06-14 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8366637B2 (en) 2002-04-19 2013-02-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8372016B2 (en) 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US8382682B2 (en) 2002-04-19 2013-02-26 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7914465B2 (en) 2002-04-19 2011-03-29 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8388551B2 (en) 2002-04-19 2013-03-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus for multi-use body fluid sampling device with sterility barrier release
US8403864B2 (en) 2002-04-19 2013-03-26 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7909777B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US8430828B2 (en) 2002-04-19 2013-04-30 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US8435190B2 (en) 2002-04-19 2013-05-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8491500B2 (en) 2002-04-19 2013-07-23 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8496601B2 (en) 2002-04-19 2013-07-30 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8556829B2 (en) 2002-04-19 2013-10-15 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8562545B2 (en) 2002-04-19 2013-10-22 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7909774B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8574168B2 (en) 2002-04-19 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a multi-use body fluid sampling device with analyte sensing
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7901365B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8636673B2 (en) 2002-04-19 2014-01-28 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8414503B2 (en) 2002-04-19 2013-04-09 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US9839386B2 (en) 2002-04-19 2017-12-12 Sanofi-Aventis Deustschland Gmbh Body fluid sampling device with capacitive sensor
US9339612B2 (en) 2002-04-19 2016-05-17 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7875047B2 (en) 2002-04-19 2011-01-25 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US8690796B2 (en) 2002-04-19 2014-04-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US8808201B2 (en) 2002-04-19 2014-08-19 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US20090192411A1 (en) * 2002-04-19 2009-07-30 Dominique Freeman Method and apparatus for penetrating tissue
US8845549B2 (en) 2002-04-19 2014-09-30 Sanofi-Aventis Deutschland Gmbh Method for penetrating tissue
US8905945B2 (en) 2002-04-19 2014-12-09 Dominique M. Freeman Method and apparatus for penetrating tissue
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9186468B2 (en) 2002-04-19 2015-11-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9089294B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US8333710B2 (en) 2002-04-19 2012-12-18 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9089678B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US9034639B2 (en) 2002-12-30 2015-05-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US8262614B2 (en) 2003-05-30 2012-09-11 Pelikan Technologies, Inc. Method and apparatus for fluid injection
US8251921B2 (en) 2003-06-06 2012-08-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US9144401B2 (en) 2003-06-11 2015-09-29 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US8945910B2 (en) 2003-09-29 2015-02-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
US8296918B2 (en) 2003-12-31 2012-10-30 Sanofi-Aventis Deutschland Gmbh Method of manufacturing a fluid sampling device with improved analyte detecting member configuration
US8668656B2 (en) 2003-12-31 2014-03-11 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US9561000B2 (en) 2003-12-31 2017-02-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
US9261476B2 (en) 2004-05-20 2016-02-16 Sanofi Sa Printable hydrogel for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US20090054811A1 (en) * 2004-12-30 2009-02-26 Dirk Boecker Method and apparatus for analyte measurement test time
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US20100327886A1 (en) * 2008-03-27 2010-12-30 Toshifumi Nakamura Measurement device, measurement system, and concentration measurement method
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation

Also Published As

Publication number Publication date Type
EP1678493A1 (en) 2006-07-12 application
JP4652334B2 (en) 2011-03-16 grant
JP4611313B2 (en) 2011-01-12 grant
US7653492B2 (en) 2010-01-26 grant
KR20060120152A (en) 2006-11-24 application
DK1678489T3 (en) 2007-08-06 grant
CA2543957A1 (en) 2005-05-19 application
US20050139489A1 (en) 2005-06-30 application
US20070276621A1 (en) 2007-11-29 application
JP4694498B2 (en) 2011-06-08 grant
ES2343184T3 (en) 2010-07-26 grant
US20050139469A1 (en) 2005-06-30 application
JP2007514928A (en) 2007-06-07 application
CA2551058C (en) 2012-10-23 grant
WO2005045412A1 (en) 2005-05-19 application
DE602004006148T2 (en) 2007-12-27 grant
JP2007514931A (en) 2007-06-07 application
EP1678489B1 (en) 2007-04-25 grant
KR20060131765A (en) 2006-12-20 application
US20050133368A1 (en) 2005-06-23 application
DE602004004929T2 (en) 2007-10-31 grant
KR101179998B1 (en) 2012-09-07 grant
DE602004006148D1 (en) 2007-06-06 grant
CA2543797C (en) 2013-01-22 grant
ES2327741T3 (en) 2009-11-03 grant
EP1678490B1 (en) 2009-07-01 grant
DK1678490T3 (en) 2009-10-05 grant
KR101201245B1 (en) 2012-11-15 grant
ES2285536T3 (en) 2007-11-16 grant
CA2551058A1 (en) 2005-05-19 application
JP2007514927A (en) 2007-06-07 application
EP1685393B1 (en) 2007-02-21 grant
EP1678490A1 (en) 2006-07-12 application
ES2282898T3 (en) 2007-10-16 grant
DE602004004929D1 (en) 2007-04-05 grant
DK1685393T3 (en) 2007-04-30 grant
US7618522B2 (en) 2009-11-17 grant
KR20070027497A (en) 2007-03-09 application
WO2005045417A1 (en) 2005-05-19 application
EP1678489A1 (en) 2006-07-12 application
JP2007514930A (en) 2007-06-07 application
JP2007514929A (en) 2007-06-07 application
EP1678491A1 (en) 2006-07-12 application
CA2543961A1 (en) 2005-05-19 application
WO2005045416A1 (en) 2005-05-19 application
WO2005045414A1 (en) 2005-05-19 application
JP2007524846A (en) 2007-08-30 application
KR20070027496A (en) 2007-03-09 application
KR20060118512A (en) 2006-11-23 application
EP1678491B1 (en) 2010-03-10 grant
WO2005045415A1 (en) 2005-05-19 application
CA2544424A1 (en) 2005-05-19 application
DE602004021835D1 (en) 2009-08-13 grant
CA2543802A1 (en) 2005-05-19 application
CA2543957C (en) 2013-01-22 grant
EP1678492A1 (en) 2006-07-12 application
EP1685393A1 (en) 2006-08-02 application
US20050183965A1 (en) 2005-08-25 application
CA2543797A1 (en) 2005-05-19 application
WO2005045413A1 (en) 2005-05-19 application
DE602004025960D1 (en) 2010-04-22 grant
US20050114062A1 (en) 2005-05-26 application

Similar Documents

Publication Publication Date Title
US20090184004A1 (en) System and method for measuring an analyte in a sample
US20070017824A1 (en) Biosensor and method of manufacture
US20070080073A1 (en) Enzymatic electrochemical biosensor
US20080105568A1 (en) Voltammetric Systems For Assaying Biological Analytes
US20090014339A1 (en) Oxidizable Species as an Internal Reference in Control Solutions for Biosensors
US20080173552A1 (en) Gated Amperometry
US20090084687A1 (en) Systems and methods of discriminating control solution from a physiological sample
US20080179197A1 (en) Gated Voltammetry
US20090194432A1 (en) System and Methods for Determination of Analyte Concentration Using Time Resolved Amperometry
EP1840219A1 (en) Systems and methods of discriminating control solution from a physiological sample
WO2008040998A2 (en) Systems and methods for determining a substantially hematocrit independent analyte concentration
US20070227912A1 (en) Methods And Apparatus For Analyzing A Sample In The Presence Of Interferents
US20080149480A1 (en) Gel formation to reduce hematocrit sensitivity in electrochemical test
US20050139489A1 (en) Method of reducing the effect of direct and mediated interference current in an electrochemical test strip
US20090280551A1 (en) A reagent formulation using ruthenium hexamine as a mediator for electrochemical test strips
EP0878713A2 (en) Method and apparatus for correcting ambient temperature effect in biosensors
WO2008150436A1 (en) Analyte determination methods and devices
US20110039286A1 (en) Temperature-Adjusted Analyte Determination For Biosensor System
US20090026094A1 (en) Two-pulse systems and methods for determining analyte concentration
US20040251132A1 (en) Reduced volume strip
WO2013030375A1 (en) Hematocrit Corrected Glucose Measurements for Electrochemical Test Strip Using Time Differential of the Signals
US20090101523A1 (en) System and Methods for Determination of Analyte Concentration Using Time Resolved Amperometry
JP2006215034A (en) Electrochemical biosensor
US20120111739A1 (en) Dual Frequency Impedance Measurement of Hematocrit in Strips
US20070246357A1 (en) Concentration Determination in a Diffusion Barrier Layer